Guy Goodwin
Chief Medical Officer COMPASS Pathways
Seminars
Thursday 17th September 2026
Transforming Psychiatric Care: From Psilocybin Breakthroughs to Scalable, Multi-Indication Therapeutics
11:30 am
- Detailing Phase 3 successes of COMP360 psilocybin in treatment resistant depression, including rapid onset, durability to 26 weeks, and FDA submission readiness
- Examining early signal-generation studies exploring COMP360’s potential in PTSD and anorexia nervosa, and planned expansions into anxiety and mood disorder indications
- Exploring the use of biomarkers, digital support tools, and retreatment protocols to optimize patient stratification, dosing, and long-term efficacy
- Discussing operational strategies, including site selection, regulatory engagement, and therapy scalability, to drive commercial readiness and global deployment
Thursday 17th September 2026
Panel Discussion: To What Degree Does Neuroplasticity Underpin Psychedelic Efficacy?
9:15 am
- Examining the evidence linking psychedelic induced synaptic and dendritic remodeling with changes in mood, cognition and emotional processing
- Exploring whether neuroplasticity is a mechanistic driver of efficacy or a downstream accompaniment to broader network level changes
- Comparing plasticity linked biomarkers, such as EEG signatures, sleep architecture shifts and neurotrophic factor changes, to determine which most reliably map onto clinical response
- Debating how much neuroplasticity is necessary, sufficient or even predictive for therapeutic benefit across different psychedelic and non psychedelic compounds
- Considering maladaptive behaviors underpinned by neuroplasticity in the brain
- How might we treat “neuroplastogens” differently: as a separate class
